Gossamer Bio
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 120, San Diego, ...Phone Number
(858) 684-1300Website
www.gossamerbio.comRevenue
$55.5 MillionStock Symbol
GOSSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Gossamer Bio
Gossamer Bio is a clinical-stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The headquarters is located in San Diego, California.Explore more
Gossamer Bio Org Chart
RO
Executive Director
SD
Head Executive Director, Clinical Supply Chai...
CC
Senior Director, Market Insights (Commercial ...
BP
Director, Clinical Quality Assurance
NS
Global Director, Congress Strategy & Executio...
IG
Director, Translational Medicine Operations
RC
Director
RP
Associate Director, CSV
DW
Associate Director, Clinical Supply Chain
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gossamer Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Gossamer Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Gossamer Bio
Gossamer Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Gossamer Bio launches new products
Earning: See what the market has to say on Gossamer Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Gossamer Bio has new funding data
Check out if Gossamer Bio is spiking on competitors!
Click to see if Gossamer Bio had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Gossamer Bio
Compare insights from companies similar to Gossamer Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gossamer Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gossamer Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gossamer Bio.
Gossamer Bio financials insights
Gather financial insights about Gossamer Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$120M
2023
Share Placement
$212M
Gossamer Bio Tech Stack
A closer look at the technologies used by Gossamer Bio
Most Recent Scoops
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Finance, Financing & Debt
Layoffs
Gossamer Bio has announced a significant reduction in force affecting approximately half of the company's workforce, alongside a sharp reduction in operating expenses as the PROSERA study winds down, as part of broader cost containment measures across the organization.
Spending/Investment, Layoffs
Person-Based
Pharmaceuticals, Clinical Operations
Gossamer Bio News & Media
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through ...
Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval. Key Investor TakeawaysGossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Gossamer Bio...Gossamer Bio shares jump after FDA update and seralutinib rights return
Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained full global rights to the therapy.Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Gossamer (GOSS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/1/2026
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gossamer Bio
Sign Up For FreeTo access detailed company insights
Gossamer Bio is a clinical-stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The headquarters is located in San Diego, California.... Read More
